Named on one round in the feed.
Since 2026-08-11
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Vaderis Therapeutics Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $152M | 2026-08-11 | [ PART ] |
No sector on record.